Vocal cord movement: can it be accurately graded?

Douglas, Catriona; Menon, Radhika; Montgomery, Jenny; Townsley, Richard; Hilmi, Omar; Buchanan, Malcolm A.; Robertson, Scott; Petropoulakis, Lykourgos; Soraghan, John J.; Lakany, Heba; MacKenzie, Kenneth

doi:10.1308/rcsann.2022.0091

Cited by 2 publications

(2 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This study suggests that clinicians should focus on vocal cord paralysis when patients report hoarsening, misswallowing, or choking after receiving capmatinib. If necessary, laryngoscopy, laryngeal electromyography, imaging, voice acoustic analysis and other auxiliary diagnosis can be performed 22 .…”

Section: Discussionmentioning

confidence: 99%

A real-world pharmacovigilance study of FDA adverse event reporting system events for Capmatinib

Qi,

Li,

Lin

et al. 2024

Sci Rep

View full text Add to dashboard Cite

Capmatinib is a potent selective mesenchymal-epithelial transition inhibitor approved in 2020 for the treatment of metastatic non-small cell lung cancer. As real-world evidence is very limited, this study evaluated capmatinib-induced adverse events through data mining of the FDA Adverse Event Reporting System database. Four disproportionality analysis methods were employed to quantify the signals of capmatinib-related adverse events. The difference in capmatinib-associated adverse event signals was further investigated with respect to sex, age, weight, dose, onset time, continent, and concomitant drug. A total of 1518 reports and 4278 adverse events induced by capmatinib were identified. New significant adverse event signals emerged, such as dysphagia, dehydration, deafness, vocal cord paralysis, muscle disorder, and oesophageal stenosis. Notably, higher risk of alanine aminotransferase and aspartate aminotransferase increases were observed in females, especially when capmatinib was combined with immune checkpoint inhibitors. Compared with Europeans and Asians, Americans were more likely to experience peripheral swelling, especially in people > 65 years of age. Renal impairment and increased blood creatinine were more likely to occur with single doses above 400 mg and in Asians. This study improves the understanding of safety profile of capmatinib.

show abstract

Section: Discussionmentioning

confidence: 99%

A real-world pharmacovigilance study of FDA adverse event reporting system events for Capmatinib

Qi,

Li,

Lin

et al. 2024

Sci Rep

View full text Add to dashboard Cite

show abstract

“…The studies are retrospective and include a low number of children with PBVCP, a fact that may be attributed to the disorder's rarity. The lack of objective lung and laryngeal measurements is an important issue because evaluations of symptoms by physicians or parents, as well as laryngoscopic findings, remain subjective [46,47]. Only LEMG was used as an objective tool in studies investigating selective laryngeal reinnervation [39,41], while there are many respiratory objective measurements available in clinical practice [48][49][50][51].…”

Section: Procedures Comparison and Perspectivesmentioning

confidence: 99%

Management of Pediatric Bilateral Vocal Fold Paralysis: A State-of-the-Art Review of Etiologies, Diagnosis, and Treatments

Lechien

2024

Children

View full text Add to dashboard Cite

Objective: This paper reviews the current literature about epidemiology, etiologies, diagnosis, and management of pediatric bilateral vocal fold paralysis (PBVFP). Methods: According to PRISMA statements, a narrative review of the current literature was conducted through the PubMed, Scopus, and Cochrane Library databases about the epidemiology, etiologies, diagnosis, and management of PBVFP. Results: PBVCP is the second most common congenital laryngeal anomaly in the pediatric population, accounting for 10% to 20% of pediatric laryngeal conditions. PBVCP is related to idiopathic (42.2%), congenital (19.7%), and neurological (16.9%) conditions. A tracheotomy is required in 60% of cases regarding stridor and dyspnea, which are the most prevalent symptoms. The diagnosis is based on the etiological features, clinical presentation, laryngoscopic findings, and objective examinations. Laryngeal electromyography may be used to support the diagnosis in difficult cases, but its reliability depends on the practitioner’s experience. The primary differential diagnosis is posterior glottis stenosis, which needs to be excluded regarding therapeutic and management differences with PBVCP. Transient surgical procedures consist of tracheotomy or laterofixation of the vocal fold. Current permanent procedures include uni- or bilateral partial arytenoidectomy, posterior transverse cordotomy, cricoid splits, and laryngeal selective reinnervation. There is no evidence of the superiority of some procedures over others. Conclusions: PBVCP is the second most common laryngeal disorder in the pediatric population. Diagnosis is based on etiological and clinical findings and may require the use of laryngeal electromyography. Therapeutic management may involve several transient or permanent surgical procedures that are associated with overall subjective improvements in symptoms, laryngeal findings, and low complication rates.

show abstract

Vocal cord movement: can it be accurately graded?

Cited by 2 publications

References 11 publications

A real-world pharmacovigilance study of FDA adverse event reporting system events for Capmatinib

A real-world pharmacovigilance study of FDA adverse event reporting system events for Capmatinib

Management of Pediatric Bilateral Vocal Fold Paralysis: A State-of-the-Art Review of Etiologies, Diagnosis, and Treatments

Contact Info

Product

Resources

About